Drugs Made In America Acquisition Corp. DMAA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.63M | 2.63M | 2.82M | 1.01M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.63M | 2.63M | 2.82M | 1.01M | -- |
| Operating Income | -2.63M | -2.63M | -2.82M | -1.01M | -- |
| Income Before Tax | 6.10M | 6.66M | 5.94M | 5.45M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.10 | 6.66 | 5.94 | 5.45 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.10M | 6.66M | 5.94M | 5.45M | -- |
| EBIT | -2.63M | -2.63M | -2.82M | -1.01M | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.19 | 0.20 | 0.19 | 0.15 | -- |
| Normalized Basic EPS | 0.12 | 0.12 | 0.12 | 0.09 | -- |
| EPS Diluted | 0.19 | 0.20 | 0.19 | 0.15 | -- |
| Normalized Diluted EPS | 0.12 | 0.12 | 0.12 | 0.09 | -- |
| Average Basic Shares Outstanding | 132.23M | 134.94M | 126.01M | 100.40M | -- |
| Average Diluted Shares Outstanding | 132.23M | 134.94M | 126.73M | 101.11M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |